UBS Group
LIMN icon

UBS Group’s Liminatus Pharma LIMN Stock Holding History

UBS Group’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.48K Buy
1,201
+866
+259% +$4.36K ﹤0.01% 9665
2026
Q2 		$1.84K Sell
335
-757
-69% -$6.54K ﹤0.01% 9460
2026
Q1 		$9.39K Buy
1,092
+704
+181% +$18.8K ﹤0.01% 8442
2025
Q4 		$11.8K Sell
388
-423
-52% -$23.5K ﹤0.01% 8145
2025
Q3 		$67.7K Buy
811
+181
+29% +$39.1K ﹤0.01% 7357
2025
Q2 		$351K Buy
+630
New +$354K ﹤0.01% 6313

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Cheviot Value Management
Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

UBS Group's LIMN Position: Q3 2026 in Review

UBS Group increased its Liminatus Pharma (LIMN) stake by 259% in Q3 2026, buying an estimated $4.36K and bringing the position to 1,201 shares worth $4.48K. The position accounts for ﹤0.01% of the portfolio, ranked #9665.

UBS Group first reported a position in LIMN in Q2 2025 and has held it in 6 quarters since. The position peaked at $351K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

  • UBS Group held 1,201 shares of Liminatus Pharma worth $4.48K as of Q3 2026.
  • UBS Group bought 866 Liminatus Pharma shares in Q3 2026, an estimated $4.36K.
  • Liminatus Pharma made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9665 holding.
  • UBS Group first reported a position in Liminatus Pharma in Q2 2025 and has held it in 6 quarters since.
  • UBS Group's Liminatus Pharma position peaked at $351K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.